Congo set to receive 70,000 Ervebo vaccines to contain Ebola outbreak, WHO says

• Of the 70,000 allocated doses, 20,000 will be used in a late-stage clinical trial to determine if Ervebo (approved only for the Zaire strain) provides protection against the Bundibugyo virus in humans
• Congo's 17th Ebola epidemic became the country's worst on record in late July, surpassing the 2018-2020 outbreak in case count with over 5,000 confirmed cases and 2,378 deaths
• WHO Director-General Tedros Ghebreyesus declared the outbreak in eastern Congo remains a global emergency, with vaccines being released from the International Coordinating Group stockpile

Congo to Receive 70,000 Ervebo Vaccine Doses for Record Ebola Outbreak

The Democratic Republic of Congo has been allocated 70,000 doses of Merck's Ervebo Ebola vaccine by the World Health Organization to combat the country's largest-ever outbreak of the deadly disease.

Key Developments

The International Coordinating Group (ICG) on Vaccine Provision approved Congo's request for vaccines from the global stockpile. Of the allocated doses, 20,000 will be used in a late-stage clinical trial to evaluate Ervebo's effectiveness against the Bundibugyo strain of Ebola.

Critical Challenge

The current outbreak is caused by the Bundibugyo species of Ebola, which has no approved vaccines or treatments. Ervebo is only approved for the more common Zaire ebolavirus strain, and it remains unknown whether it will be effective against Bundibugyo in humans. The WHO emphasized the importance of clinical trials to generate crucial evidence.

Outbreak Statistics

• Confirmed cases: Over 5,000
• Death toll: 2,378
• Timeline: Congo's 17th Ebola epidemic became the country's worst by case count in late July, surpassing the 2018-2020 outbreak

WHO Director-General Tedros Ghebreyesus declared the outbreak remains a global emergency.

Organizations Involved

The ICG is a partnership between WHO, the International Federation of the Red Cross and Red Crescent Societies, Médecins Sans Frontières, and UNICEF.

Market Implications

Merck is the key company involved as manufacturer of Ervebo. The unprecedented scale of this outbreak and experimental use of Ervebo against a different Ebola strain highlights both the urgent need for broader-spectrum treatments and potential opportunities for vaccine development in the pharmaceutical sector.